Report Overview: Partnering deals and alliances with big pharma by marketresearchreports.biz

  • 102 views
Uploaded on


Partnering Deals and Alliances with Big Pharma
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/164255
For All Latest Reports Kindly visit: http://www.marketresearchreports.biz






More in: Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
102
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Partnering Deals and Alliances with Big Pharma The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits: Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick identification potential partners Partnering therapy focus revealed Partnering activity since 2007 – number of deals per year Full listing of partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity by technology type Activity by therapeutic area Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents Understand the key deal terms the company has agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. This premier report provides all the information you require to better understand big pharma partnering. One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big pharma companies dealmaking trends over the last four years. This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst Chapter 2 lists the top 50 leading big pharma companies based on 2012 pharmaceutical revenues and dealmaking activity since 2007. Chapter 3 reviews the top partnering and M&A deals of 2007-2013 according to reported deal size. Chapter 4 provides a summary on best practice on how to submit an opportunity to big pharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner. Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big pharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings. The main body of the report is provided in chapter 6. In-depth profiles of every big pharma company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type. Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC. One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship. Understanding the flexibility of a prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil Partnering Deals and Alliances with Big Pharma
  • 2. is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This data driven report contains over 3,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. In summary, the report provides the reader with the tools necessary to make successful contact with the right big pharma partners effectively and efficiently. Key benefits Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits: Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick identification potential partners Partnering therapy focus revealed Partnering activity since 2007 – number of deals per year Full listing of partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity by technology type Activity by therapeutic area Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents Understand the key deal terms the company has agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Partnering Deals and Alliances with Big Pharma is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big pharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s partnering. Partnering Deals and Alliances with Big Pharma includes: Detailed company profiles for each of the top 50 big pharma companies, including: Partnering interests and indications Partnering activity since 2007 Partner companies since 2007 Partnering activity since 2007 by: Partner company Deal type Industry sector Stage of development Technology type Therapy area Over 300 charts showing the dealmaking activity of each company since 2007 The tools to enable effective and efficient preparation for partnering negotiation with big pharma 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available The leading M&A and partnering deals by value 2007-2013 The Partnering Deals and Alliances with Big Pharma report also provides comprehensive access to available contract documents for each of the fifty big pharma companies. Analyzing actual company agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subscontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits: Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick identification potential partners Partnering therapy focus revealed Partnering activity since 2007 – number of deals per year Full listing of partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity by technology type Activity by therapeutic area Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available Insight into the terms Partnering Deals and Alliances with Big Pharma
  • 3. included in a partnering agreement, together with real world clause examples, via contract documents Understand the key deal terms the company has agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies table Of Content executive Summary chapter 1 – Introduction chapter 2 – Big Pharma Top 50 Dealmaking Activity 2.1. Introduction 2.2. Big Pharma Partnering Over The Years 2.4. Big Pharma Partnering By Deal Type 2.5. Big Pharma Partnering Industry Sector 2.6. Big Pharma Partnering By Stage Of Development 2.7. Big Pharma Partnering By Technology Type 2.8. Big Pharma Partnering By Therapy Area 2.9. Big Pharma M&a Over The Years chapter 3 – Top Big Pharma Deals By Value 3.1. Introduction 3.2. Big Pharma Partnering 3.3. Big Pharma M&a chapter 4 – Submitting Opportunities To Big Pharma 4.1. How To Submit An Opportunity 4.2. Opportunity Submission Template 4.3. Sending Emails 4.4. Face To Face At Partnering Events 4.5. Online Submission Forms chapter 5 – Forthcoming Big Pharma Partnering Events 5.1. Forthcoming Events chapter 6 – Big Pharma Company Profiles 6.1. Introduction 6.2. Field Definitions 6.3. Company Profiles abbott actavis Inc.( Formerly Watson) allergan amgen astellas astrazeneca Partnering Deals and Alliances with Big Pharma
  • 4. baxter International bayer biogen Idec boehringer Ingelheim bristol-myers Squibb celgene csl daiichi Sankyo dainippon Sumitomo eisai eli Lilly endo Pharmaceuticals forest Laboratories fresenius galderma gilead Sciences glaxosmithkline grifols hospira johnson & Johnson kyowa Hakko Kirin lundbeck menarini merck & Co merck Kgaa mitsubishi Tanabe mylan novartis novo Nordisk otsuka pfizer purdue ranbaxy Laboratories roche sanofi servier shionogi shire stada takeda teva ucb valeant warner Chilcott chapter 7 – Resources Partnering Deals and Alliances with Big Pharma
  • 5. appendices appendix 1 – Deal Type Definitions appendix 2 – Example Contract Document about Wildwood Ventures current Partnering current Agreements recent Titles From Currentpartnering order Form – Reports Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.com Website: www.marketresearchreports.biz Partnering Deals and Alliances with Big Pharma